Video abstract of review paper “A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder” published in the open access journal Therapeutics and Clinical Risk Management by authors Chue and Chue. Abstract: Schizoaffective disorder (SCA) is a chronic and disabling mental illness that presents with mixed symptoms of schizophrenia and affective disorders. SCA is recognized as a discrete disorder, but with greater heterogeneity and symptom overlap, leading to difficulty and delay in diagnosis. Although the overall prognosis is intermediate between schizophrenia and mood disorders, SCA is associated with higher rates of suicide and hospitalization than schizophrenia. No treatment guidelines exist for SCA, and treatment is frequently complex, involving off-label use and polypharmacy (typically combinations of antipsychotics, mood stabilizers, and antidepressants). Oral paliperidone extended-release was the first agent to be approved for the treatment of SCA. As in schizophrenia and bipolar disorder, adherence to oral medications is poor, further contributing to suboptimal outcomes. The use of an antipsychotic in a long-acting injection (LAI) addresses adherence issues, thus potentially reducing relapse. Paliperidone palmitate represents the LAI formulation of paliperidone. In a long-term, double-blind, randomized, controlled trial of adult patients (n=334; intent-to-treat [ITT]) with SCA, paliperidone long-acting injection (PLAI) significantly delayed risk of relapse compared to placebo (hazard ratio 2.49, 95% confidence interval, 1.55–3.99; P is less than 0.001). This study demonstrated the efficacy and safety of PLAI when used as either monotherapy or adjunctive therapy for the maintenance treatment of SCA. The results are consistent with a similarly designed study conducted in patients with schizophrenia, which suggests a benefit in the long-term control of not only psychotic but also affective symptoms. No new safety signals were observed. When used in monotherapy, PLAI simplifies treatment by reducing complex pharmacotherapy and obviating the necessity for daily oral medications. PLAI is the second agent, and the first LAI, to be approved for the treatment of SCA; as an LAI formulation, there is the advantage of improved adherence and simplified treatment in the long-term management of SCA. Read the full paper here: https://www.dovepress.com/a-critical-appraisal-of-paliperidone-long-acting-injection-in-the-trea-peer-reviewed-article-TCRM
Showing What the Invega Sustenna Injectable is About Thanks for watching!! I'm Lyn and I'm a Psych nurse at 2 facilities. I normally work 12hr shifts, however, when I pickup, I usually work 8. I have been a nurse for 9 years, 7 of which are with Psych, 2 with Med Surg. I 've also had some experience with Oncology. Psych or Psychiatry is used interchangeably with Behavioral Health or Mental Health. Please like, comment, and subscribe, it helps me a lot and I would appreciate it. : ) If you have any questions, please comment and I'll be sure to respond!
Risperdal consta how To use
Midwestern University Department of Family Medicine
Invega Sustenna how to video shot for Janssen, Johnson & Johnson. Multi-camera studio shoot.
Video abstract of original research "Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia" published in open access journal Neuropsychiatric Disease and Treatment by Jennifer Kern Sliwa, Cynthia A Bossie, Dong-Jing Fu, et al. Conclusion: The long-term tolerability of paliperidone palmitate was generally similar in recently diagnosed schizophrenia subjects and those with more chronic illness, with the exception of some prolactin-related measures. Read this original research and sign up to receive Neuropsychiatric Disease and Treatment here: http://www.dovepress.com/long-term-tolerability-of-once-monthly-injectable-paliperidone-palmita-peer-reviewed-article-NDT
Updated Deltoid IM Injection Video: https://www.youtube.com/watch?v=DBHnd3N-5Ns Deltoid injection site of an IM intramuscular shot that includes specific deltoid technique and demonstration. Learn how to give an IM intramuscular injection in the deltoid muscle for nursing students, new nurses, or other healthcare professions. Giving an injection in the deltoid muscle is very common in the health care world and is most commonly used for influenza "flu" shot vaccination. The deltoid muscle is found in the arm, right below the acromion process. I demonstrate how to find the deltoid landmarks prior to injection and how to aspirate the syringe. Subscribe: http://www.youtube.com/subscription_center?add_user=registerednursern Nursing School Supplies: http://www.registerednursern.com/the-ultimate-list-of-nursing-medical-supplies-and-items-a-new-nurse-student-nurse-needs-to-buy/ Nursing Job Search: http://www.registerednursern.com/nursing-career-help/ Visit our website RegisteredNurseRN.com for free quizzes, nursing care plans, salary information, job search, and much more: http://www.registerednursern.com Check out other Videos: https://www.youtube.com/user/RegisteredNurseRN/videos Popular Playlists: "NCLEX Study Strategies": https://www.youtube.com/playlist?list=PLQrdx7rRsKfWtwCDmLHyX2UeHofCIcgo0 "Nursing Skills Videos": https://www.youtube.com/playlist?list=PLQrdx7rRsKfUhd_qQYEbp0Eab3uUKhgKb "Nursing School Study Tips": https://www.youtube.com/playlist?list=PLQrdx7rRsKfWBO40qeDmmaMwMHJEWc9Ms "Nursing School Tips & Questions": https://www.youtube.com/playlist?list=PLQrdx7rRsKfVQok-t1X5ZMGgQr3IMBY9M "Teaching Tutorials": https://www.youtube.com/playlist?list=PLQrdx7rRsKfUkW_DpJekN_Y0lFkVNFyVF "Types of Nursing Specialties": https://www.youtube.com/playlist?list=PLQrdx7rRsKfW8dRD72gUFa5W7XdfoxArp "Healthcare Salary Information": https://www.youtube.com/playlist?list=PLQrdx7rRsKfVN0vmEP59Tx2bIaB_3Qhdh "New Nurse Tips": https://www.youtube.com/playlist?list=PLQrdx7rRsKfVTqH6LIoAD2zROuzX9GXZy "Nursing Career Help": https://www.youtube.com/playlist?list=PLQrdx7rRsKfVXjptWyvj2sx1k1587B_pj "EKG Teaching Tutorials": https://www.youtube.com/playlist?list=PLQrdx7rRsKfU-A9UTclI0tOYrNJ1N5SNt "Personality Types": https://www.youtube.com/playlist?list=PLQrdx7rRsKfU0qHnOjj2jf4Hw8aJaxbtm "Dosage & Calculations for Nurses": https://www.youtube.com/playlist?list=PLQrdx7rRsKfUYdl0TZQ0Tc2-hLlXlHNXq "Diabetes Health Managment": https://www.youtube.com/playlist?list=PLQrdx7rRsKfXtEx17D7zC1efmWIX-iIs9 http://www.registerednursern.com/intramuscular-injection-how-to-give-an-im-injection/
I have been taking Invega for almost three years now, and I really like it. In this video, I discuss how Invega has affected me and some of the side effects. I hope this video counteracts the negativity about Invega and that you will give it a try for yourself if you have Schizophrenia or Schizoaffective Disorder. Here is a link to the post on the blog: http://wilfolio.com/2016/11/11/i-like-invega/
This training helps providers identify intramuscular (IM) injection sites. A needle is used to inject the vaccine into the muscle. The appropriate site for an intramuscular injection for those under 2 years of age is the vastus lateralis muscle. The deltoid muscle over the triceps area of the upper arm is preferred for persons 3 years of age and older. Safe injection practices minimize risk of injuries, infections, and non-infectious adverse events for both patients and providers. Health care providers are always advised to observe patients for 15 minutes after vaccination. Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/vaccines/videos/low-res/Intramuscular/IM_Sites_All_Ages_LowRes.mp4
Video abstract of original research paper "Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics" published in the open access journal Neuropsychiatric Disease and Treatment by Alphs L, Bossie1 CA, Sliwa JK, et al. Background: This post hoc subgroup analysis of a randomized, double-blind trial evaluated the response to treatment with two long-acting injectable atypical antipsychotics, ie, paliperidone palmitate and risperidone long-acting injectable (RLAI), in subjects with schizophrenia experiencing clinically significant symptoms despite recent treatment with oral risperidone only or other oral antipsychotics. Methods: Adult subjects were eligible for the 13-week, double-blind, double-dummy trial (NCT00589914) if they had an established diagnosis of schizophrenia for at least one year and a Positive and Negative Syndrome Scale (PANSS) total score of 60--120 inclusive at screening. Subjects received either paliperidone palmitate (234 mg, day 1; 156 mg, day 8; then once-monthly flexible dosing) or RLAI (25--50 mg biweekly, with oral risperidone supplementation on days 1--28), plus matched placebo injections/tablets. Conclusion: Treatment with paliperidone palmitate or RLAI resulted in a significant reduction in the symptoms of schizophrenia irrespective of previous recent treatment with oral risperidone only or other oral antipsychotics. For subjects who had previously received oral risperidone only, the difference in formulation was the main change in the intervention because the molecule delivered remained the same or similar. These data support the contribution of a long-acting formulation to improving the treatment response and suggest that nonadherence may be a significant contributor to inadequate efficacy of oral formulations in subjects with schizophrenia. Read this original research and sign up to receive Neuropsychiatric Disease and Treatment here: http://www.dovepress.com/paliperidone-palmitate-and-risperidone-long-acting-injectable-in-subje-peer-reviewed-article-NDT